Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics ( (SYRE) ) has shared an update.
On April 13, 2026, Spyre Therapeutics reported positive 12-week induction topline results from Part A of its Phase 2 SKYLINE trial evaluating SPY001 in patients with moderate-to-severely active ulcerative colitis. The extended half-life anti-α4β7 antibody met its primary endpoint with a statistically significant 9.2-point reduction in Robarts Histopathology Index score, alongside clinically meaningful secondary outcomes, including 40% clinical remission and 51% endoscopic improvement, and was well tolerated with low rates of adverse events and no drug-related serious events.
The company also confirmed that recruitment for SKYLINE Part A is complete and that enrollment is underway for Part B, which will test SPY001, SPY002, and SPY003 as monotherapies and in combination regimens against a shared placebo. These data bolster Spyre’s bid for a potential best-in-class anti-α4β7 therapy and support its strategy of using SPY001 as a backbone for combination approaches in inflammatory bowel disease, with additional proof-of-concept readouts from other cohorts expected in 2026 and full Part B induction data targeted for 2027.
The most recent analyst rating on (SYRE) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
The score is anchored by weak operating fundamentals (minimal revenue, sizable losses, and continued cash burn), partially offset by a strong, debt-free balance sheet and positive corporate developments with funded runway. Technicals add support due to a clear uptrend, while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company listed on Nasdaq that focuses on long-acting antibodies and antibody combinations aimed at redefining treatment standards for inflammatory bowel disease and rheumatic diseases. Its pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23, positioning the company in the competitive immunology and gastroenterology markets.
The company is developing multiple investigational agents within platform trials such as SKYLINE and SKYWAY, using both monotherapy and rational combination approaches. By concentrating on gut-selective mechanisms and extended dosing intervals, Spyre is targeting improved efficacy, safety, and convenience profiles compared with existing biologic therapies for immune-mediated diseases.
Average Trading Volume: 746,796
Technical Sentiment Signal: Buy
Current Market Cap: $4.03B
Learn more about SYRE stock on TipRanks’ Stock Analysis page.